Jiangxi Rimag Group Co., Ltd. Class H ( (HK:2522) ) has issued an announcement.
Jiangxi Rimag Group Co., Ltd. announced a significant decline in revenue and profit for the year ended December 31, 2024, primarily due to macroeconomic fluctuations and regulatory adjustments in the medical industry. Despite these challenges, the company strategically delayed certain projects to align with future demand and focused on constructing new imaging centers. The listing on the Stock Exchange in June 2024 provided a financial boost, allowing the company to expand its imaging network and pursue international growth. With favorable national policies and a rebound in industry demand, the company is poised for stable growth, leveraging its core competencies and international strategy.
More about Jiangxi Rimag Group Co., Ltd. Class H
Jiangxi Rimag Group Co., Ltd. is a leading medical group in China specializing in medical imaging. It operates a comprehensive medical imaging platform providing diversified services across the entire medical imaging industry chain. The company has a strong domestic presence and leverages Hong Kong and Macao to expand into international markets, focusing on digital innovation and intelligent budget management to optimize operations.
YTD Price Performance: -71.92%
Average Trading Volume: 748,720
Technical Sentiment Signal: Strong Buy
For an in-depth examination of 2522 stock, go to TipRanks’ Stock Analysis page.